Hp-𝜷-CD-Voriconazole In Situ Gelling System for Ocular Drug Delivery: In Vitro, Stability, and Antifungal Activities Assessment

Table 5

A comparative study of anti-fungal activity of voriconazole in situ gel against Candida albicans and Aspergillus fumigatus.

S.NO.	Solution	Mean of diameter of zone of inhibition; (mm) ± SE	Range of zone size; (mm)	Coefficient of; variance; (%)
Candida albicans	Test	32.33 ± 0.16	32.11–32.48	0.49
	Control 1	10.04 ± 0.03	10.01–10.12	0.30
	Control 2	12.05 ± 0.04	12.01–12.09	0.04
Aspergillus fumigates	Test	68.19 ± 0.56	68.01–69.01	0.81
	Control 1	10.02 ± 0.01	10.01–10.14	0.15
	Control 2	12.07 ± 0.02	12.05–12.09	0.17

∗Test—VG9 formulation.
∗Control 1—VG9 formulation without drug.
∗Control 2—VG9 formulation without HP-β-CD.